Literature DB >> 23566495

Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment.

Karine Baumstarck1, Laurent Boyer2, Mohamed Boucekine2, Valérie Aghababian3, Nathalie Parola4, Christophe Lançon4, Pascal Auquier2.   

Abstract

BACKGROUND: Impaired executive functions are among the most widely observed in patients suffering from schizophrenia. The use of self-reported outcomes for evaluating treatment and managing care of these patients has been questioned. The aim of this study was to provide new evidence about the suitability of self-reported outcome for use in this specific population by exploring the internal structure, reliability and external validity of a specific quality of life (QoL) instrument, the Schizophrenia Quality of Life questionnaire (SQoL18).
DESIGN: cross-sectional study. INCLUSION CRITERIA: age over 18 years, diagnosis of schizophrenia according to the DSM-IV criteria. DATA COLLECTION: sociodemographic (age, gender, and education level) and clinical data (duration of illness, Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia); QoL (SQoL18); and executive performance (Stroop test, lexical and verbal fluency, and trail-making test). Non-impaired and impaired populations were defined for each of the three tests. For the six groups, psychometric properties were compared to those reported from the reference population assessed in the validation study.
RESULTS: One hundred and thirteen consecutive patients were enrolled. The factor analysis performed in the impaired groups showed that the questionnaire structure adequately matched the initial structure of the SQoL18. The unidimensionality of the dimensions was preserved, and the internal/external validity indices were close to those of the non-impaired groups and the reference population.
CONCLUSIONS: Our study suggests that executive dysfunction did not compromise the reliability or validity of self-reported disease-specific QoL questionnaire.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23566495     DOI: 10.1016/j.schres.2013.03.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

3.  How to interpret multidimensional quality of life questionnaires for patients with schizophrenia?

Authors:  Pierre Michel; Pascal Auquier; Karine Baumstarck; Anderson Loundou; Badih Ghattas; Christophe Lançon; Laurent Boyer
Journal:  Qual Life Res       Date:  2015-04-09       Impact factor: 4.147

4.  Modernizing quality of life assessment: development of a multidimensional computerized adaptive questionnaire for patients with schizophrenia.

Authors:  Pierre Michel; Karine Baumstarck; Christophe Lancon; Badih Ghattas; Anderson Loundou; Pascal Auquier; Laurent Boyer
Journal:  Qual Life Res       Date:  2017-03-25       Impact factor: 4.147

5.  Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis.

Authors:  Tyler B Grove; Ivy F Tso; Jinsoo Chun; Savanna A Mueller; Stephan F Taylor; Vicki L Ellingrod; Melvin G McInnis; Patricia J Deldin
Journal:  Psychiatry Res       Date:  2016-06-25       Impact factor: 3.222

6.  Validation of the psychometrics properties of a French quality of life questionnaire among a cohort of renal transplant recipients less than one year.

Authors:  Davy Beauger; Dorothée Fruit; Claire Villeneuve; Marie-Laure Laroche; Elisabeth Jouve; Annick Rousseau; Laurent Boyer; Stéphanie Gentile
Journal:  Qual Life Res       Date:  2016-03-26       Impact factor: 4.147

7.  Medication and aggressiveness in "real world" schizophrenia: current issues and perspectives.

Authors:  Guillaume Fond; Laurent Boyer
Journal:  Psychopharmacology (Berl)       Date:  2016-06       Impact factor: 4.530

8.  The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project.

Authors:  Laurent Boyer; Sara Fernandes; Melanie Faugere; Raphaelle Richieri; Pascal Auquier; Guillaume Fond; Christophe Lancon
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

9.  Letter to the editor: Critique of Bahorik et al. (2013)--'Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors'.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Marvin S Swartz; M Scott Young; Brian G Sellers
Journal:  Psychol Med       Date:  2013-10-28       Impact factor: 7.723

10.  Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study.

Authors:  M Faugere; J A Micoulaud-Franchi; M Alessandrini; R Richieri; C Faget-Agius; P Auquier; C Lançon; L Boyer
Journal:  Sci Rep       Date:  2015-06-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.